NextCell Pharma AB (STO:NXTCL)

NextCell Pharma AB Cash Flow Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Aug 31, 2025	Aug 31, 2024	Aug 31, 2023	Aug 31, 2022
Net Income	-38.79	-35.14	-41.96	-39.81	-34.55
Depreciation & Amortization	2.49	2.52	0.97	0.45	0.46
Loss (Gain) From Sale of Assets	-	-	-	-	0.14
Other Operating Activities	-	-	-0	-	-
Change in Accounts Receivable	-2.41	-1.79	3.17	-7.59	-1.56
Change in Inventory	0.22	-	0.25	-0.02	-0.77
Change in Accounts Payable	-3.6	-3.47	5.26	-1.03	0.64
Change in Other Net Operating Assets	0.33	-0.98	-5.47	4.18	2.33
Operating Cash Flow	-41.76	-38.86	-37.78	-43.83	-33.31
Capital Expenditures	-4.81	-4.18	-0.08	-4.1	-7.59
Investment in Securities	-0.3	-0.06	-0	-0	-1.76
Other Investing Activities	-0	-0	-	-	-
Investing Cash Flow	-5.11	-4.24	-0.08	-4.1	-9.35
Long-Term Debt Issued	-	1.1	0.8	0.84	0.61
Total Debt Issued	1.05	1.1	0.8	0.84	0.61
Net Debt Issued (Repaid)	1.05	1.1	0.8	0.84	0.61
Issuance of Common Stock	36.56	36.56	40.09	-	-
Other Financing Activities	-2.63	-2.63	-6.25	-	-
Financing Cash Flow	34.99	35.03	34.63	0.84	0.61
Miscellaneous Cash Flow Adjustments	-0	0	-	-	-
Net Cash Flow	-11.89	-8.07	-3.23	-47.09	-42.05
Free Cash Flow	-46.57	-43.05	-37.86	-47.92	-40.9
Free Cash Flow Margin	-473.62%	-389.04%	-335.70%	-343.41%	-656.63%
Free Cash Flow Per Share	-	-0.56	-0.93	-1.39	-1.19
Cash Interest Paid	0	0	0	0	0.01
Levered Free Cash Flow	-	-30.33	-22.93	-33.74	-28.38
Unlevered Free Cash Flow	-	-30.33	-22.93	-33.74	-28.37
Change in Working Capital	-5.47	-6.24	3.21	-4.46	0.65

Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.